inflammatory diseases

News

NICE backs Novartis' Cosentyx for underdiagnosed back condit...

NICE has extended the range of indications that Novartis' Cosentyx can be prescribed for by the NHS in England, giving a green light for its use in non-radiographic axial spondyloarthritis

News

Alvotech files lawsuit challenging AbbVie's Humira patent th...

Biosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira in the US.

News

Sanofi licences in potential oral IL-17 drug from UK's C4X D...

Sanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal worth up to €414 million ($492 million).

News

Amgen buys inflammatory diseases drug firm Rodeo for up to $...

Amgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its potential tissue repair drugs in a deal worth up to $721 million.

News

Lilly's mirikuzumab hits target in phase 3 ulcerative coliti...

A phase 3 trial of Lilly’s inflammatory diseases challenger mirikizumab in ulcerative colitis has met its target – potentially adding further competition to a crowded market.

News